2 classy ASX healthcare stocks to buy before the next market surge

If sentiment shifts, these global powerhouses could lead the rally.

ASX healthcare stocks have taken a hit lately, but that could be setting up opportunity.

Two of the ASX's biggest names in the sector are under pressure, with CSL Ltd (ASX: CSL) down 33% over the past six months and ResMed Inc (ASX: RMD) sliding 20% over the same period at the time of writing.

So, are these high-quality names primed for a comeback?

A group of people in a corporate setting do a collective high five.

Image source: Getty Images

CSL: Global leader in plasma therapies

CSL has fallen out of favour, but the underlying business still looks incredibly strong.

This is a global leader in plasma therapies and vaccines, supplying critical treatments for chronic and rare diseases. Demand for its products is highly resilient — patients need them regardless of economic conditions.

That gives the $67 billion ASX healthcare stock a defensive edge, backed by recurring revenue and strong global demand.

Recent results have been softer, with margin pressure, restructuring costs, and policy changes weighing on performance. That's played a big role in the share price decline.

But there are signs of recovery. Plasma collections are improving, margins are stabilising, and its vaccine business, Seqirus, continues to diversify earnings. This looks more like a reset than a structural decline.

The main risks? Ongoing margin pressure, currency headwinds, and any delays in earnings recovery.

Still, analysts remain firmly in the corner of the ASX healthcare stock.

Broker sentiment is broadly positive, with most maintaining buy or outperform ratings. The average 12-month price target sits around $214.00 — implying 54% upside.

ResMed: Market leader in sleep apnea

ResMed has also been caught in the recent healthcare and tech sell-off, but its long-term story remains compelling.

This ASX healthcare stock is a global leader in sleep apnea devices and digital health solutions. Its products improve patient outcomes and are increasingly integrated with cloud-based platforms — creating a sticky, recurring revenue model.

A major growth driver is rising awareness and diagnosis of sleep disorders, alongside expansion in digital health and remote monitoring.

So why the sell-off? Concerns around competition, particularly from weight-loss drugs potentially reducing sleep apnea cases, have weighed on sentiment. Like CSL, it has also been hit by broader market rotation away from growth stocks.

That said, the business continues to deliver solid performance and innovation.

The risks include competitive pressures, regulatory changes, and any slowdown in patient growth.

But analysts remain largely upbeat on the ASX healthcare stock.

The average price target sits at $307.95, suggesting upside of around 37%. The most bullish forecasts go even further, tipping the stock could reach $371.80, implying gains of up to 66%.

Foolish Takeaway

CSL and ResMed have both been sold off, but their core businesses remain strong.

If sentiment shifts and earnings momentum improves, these ASX healthcare stocks could be well positioned to lead the next market surge.

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A woman looks nonplussed as she holds up a handful of Australian $50 notes.
Healthcare Shares

At $199, are CSL shares a bargain buy or a risky investment?

Here's my verdict on the ASX biotech stock.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

Falling pills in a blue background.
Healthcare Shares

Mayne shares are up 80% on takeover news, but there's still money to be made

Major shareholders are backing the deal in.

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »